{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:52:23Z","timestamp":1793778743136,"version":"4.6.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1038\/s41375-019-0539-0","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T11:02:36Z","timestamp":1566212556000},"page":"224-233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":226,"title":["A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial"],"prefix":"10.1038","volume":"34","author":[{"given":"Thierry","family":"Facon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Meuleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Belch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Renwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Tempescul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Attal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Lorraine Chretien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shien","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sturniolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Tinel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Silvia Monzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Houck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Yves Mary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"key":"539_CR1","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER cancer statistics review, 1975-2013. \nhttp:\/\/seer.cancer.gov\/csr\/1975_2013\/\n\n. Updated September 12, 2016. Accessed Jan 2019."},{"key":"539_CR2","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516\u201320.","journal-title":"Blood"},{"key":"539_CR3","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122\u201328.","journal-title":"Leukemia"},{"key":"539_CR4","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma: an International Myeloma Working Group report. Blood. 2015;125:2068\u201374.","journal-title":"Blood"},{"key":"539_CR5","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/sj.bjc.6601231","volume":"89","author":"SP Blagden","year":"2003","unstructured":"Blagden SP, Charman SC, Sharples LD, Magee LR, Gilligan D. Performance status score: do patients and their oncologists agree? Br J Cancer. 2003;89:1022\u201327.","journal-title":"Br J Cancer"},{"key":"539_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/geront\/10.1_Part_1.20","volume":"10","author":"S Katz","year":"1970","unstructured":"Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist. 1970;10:20\u201330.","journal-title":"Gerontologist"},{"key":"539_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"MP Lawton","year":"1969","unstructured":"Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179\u201386.","journal-title":"Gerontologist"},{"key":"539_CR8","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology: multiple myeloma. Version 1.2019. \nhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf\n\n. Accessed 7 Jan 2019."},{"key":"539_CR9","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320.","journal-title":"J Clin Oncol"},{"key":"539_CR10","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","volume":"101","author":"M Engelhardt","year":"2016","unstructured":"Engelhardt M, Dold SM, Ihorst G, Zober A, Moller M, Reinhardt H, et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016;101:1110\u201319.","journal-title":"Haematologica"},{"key":"539_CR11","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/ajh.24532","volume":"91","author":"P Milani","year":"2016","unstructured":"Milani P, Vincent Rajkumar S, Merlini G, Kumar S, Gertz MA, Palladini G, et al. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol. 2016;91:1129\u201334.","journal-title":"Am J Hematol"},{"key":"539_CR12","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906\u201317.","journal-title":"N Engl J Med"},{"key":"539_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","volume":"131","author":"T Facon","year":"2018","unstructured":"Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131:301\u201310.","journal-title":"Blood"},{"key":"539_CR14","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3324\/haematol.2014.120121","volume":"100","author":"M Delforge","year":"2015","unstructured":"Delforge M, Minuk L, Eisenmann JC, Arnulf B, Canepa L, Fragasso A, et al. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica. 2015;100:826\u201333.","journal-title":"Haematologica"},{"key":"539_CR15","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1182\/blood.V126.23.4239.4239","volume":"126","author":"T Facon","year":"2015","unstructured":"Facon T, Hulin C, Dimopoulos MA, Belch A, Meuleman N, Mohty M, et al. A frailty scale predicts outcomes of patients with newly diagnosed multiple myeloma who are ineligible for transplant treated with continuous lenalidomide plus low-dose dexamethasone on the first trial. Blood. 2015;126:4239.","journal-title":"Blood"},{"key":"539_CR16","unstructured":"van Reenen M, Janssen B EQ-5D-5L user guide. \nhttps:\/\/euroqol.org\/wp-content\/uploads\/2016\/09\/EQ-5D-5L_UserGuide_2015.pdf\n\n. Published April 2015. Accessed 7 Jan 2019."},{"key":"539_CR17","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"539_CR18","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.eurger.2013.07.230","volume":"4","author":"A Cruz-Jentoft","year":"2013","unstructured":"Cruz-Jentoft A, Oiartzabal I, Fern\u00e1ndez-Lago C, Gonz\u00e1lez B, Gironella M, Zudaire MT, et al. Validation of a comprehensive health status assessment scale in older patients (\u2265 65 years) with hematological malignancies. GAH study. Eur Geriatr Med. 2013;4:S70.","journal-title":"Eur Geriatr Med"},{"key":"539_CR19","doi-asserted-by":"publisher","unstructured":"Mian HS, Wildes TM, Fiala MA. Development of a Medicare Health Outcomes Survey deficit\u2014accumulation frailty index and its application to older patients with newly diagnosed multiple myeloma. JCO Clin Cancer Inform. 2018. e-pub 25 July 2018; \nhttps:\/\/doi.org\/10.1200\/CCI.18.00043\n\n.","DOI":"10.1200\/CCI.18.00043"},{"key":"539_CR20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1200\/JCO.20.2.494","volume":"20","author":"L Repetto","year":"2002","unstructured":"Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20:494\u2013502.","journal-title":"J Clin Oncol"},{"key":"539_CR21","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1002\/cncr.23856","volume":"113","author":"ID Schnadig","year":"2008","unstructured":"Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, et al. Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer. Cancer. 2008;113:2205\u201314.","journal-title":"Cancer"},{"key":"539_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/ajh.24676","volume":"92","author":"R Warsame","year":"2017","unstructured":"Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. Am J Hematol. 2017;92:435\u201340.","journal-title":"Am J Hematol"},{"key":"539_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/cncr.29717","volume":"122","author":"WA Wood","year":"2016","unstructured":"Wood WA, Le-Rademacher J, Syrjala KL, Jim H, Jacobsen PB, Knight JM, et al. Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902). Cancer. 2016;122:91\u20138.","journal-title":"Cancer"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0539-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0539-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0539-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:37:57Z","timestamp":1684604277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0539-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["539"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0539-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]},"assertion":[{"value":"8 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TF has received fees for a consulting\/advisory role from Amgen, Celgene, Janssen, Karyopharm, PharmaMar, and Takeda; and speakers bureau fees from Amgen, Celgene, Janssen, and Takeda. MAD reports honoraria from Amgen, Novartis, Celgene, Takeda, Genesis Pharmaceuticals, Janssen-Cilag, and Bristol-Myers Squibb; a consulting\/advisory role for Amgen, Janssen-Cilag, Takeda, and Celgene; research funding from Janssen-Cilag and Amgen; and travel accommodations from Janssen-Ortho, Genesis Pharmaceuticals, and Amgen. AB, NM, W-MC, KK, CR, SM, MA, XL, MLC, JYM, and SG have nothing to report. MM has received honoraria from Celgene, Janssen, Bristol-Myers Squibb, Takeda, Novartis, and Amgen; fees for a consulting\/advisory role from Celgene, Janssen, Bristol-Myers Squibb, Takeda, Novartis, and Amgen; speakers bureau fees from Janssen and Sanofi; research funding from Sanofi; and travel accommodations\/expenses from Sanofi, JAZZ, Novartis, Janssen, and Amgen. EZ reports honoraria and speakers bureau fees from Celgene, Janssen, and Amgen. PR-O reports honoraria and speakers bureau fees from Celgene, Janssen, MSD, and Bristol-Myers Squibb. WR reports honoraria from Celgene, travel from Amgen, and speakers bureau fees from Bayer. AT reports export board committee for Gilead. EB has received fees for a consulting\/advisory role from Celgene. PM has received honoraria from Celgene, Takeda, Novartis, Amgen, and Janssen-Cilag; and fees for a consulting\/advisory role from Celgene, Takeda, Novartis, Amgen, and Janssen. MM reports honoraria from Celgene, Janssen, Takeda, Novartis, and Amgen; a consulting\/advisory role for Celgene, Janssen, Takeda, Novartis, and Amgen; and travel accommodations\/expenses from Janssen, Celgene, Takeda, and Novartis. HL has received speakers bureau fees from Celgene, Janssen, Takeda, and Amgen; and research funding from Takeda and Amgen. MS, AT, BC, VH, and MSM are employees of and own stock in Celgene. CH has received honoraria from Celgene, Amgen, Bristol-Myers Squibb, Novartis, Janssen-Cilag, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}